- The instrument segment will experience double-digit growth.
- The research segment is projected to secure value of nearly $240 million.
- Multiplex biomarker imaging market in North America is estimated to reach a value of more than $500 million.
A study on the global multiplex biomarker imaging market has been conducted by Research Report Insights during the assessment period (2017-2027). The study reveals the value forecast of the market and highlights factors influencing the growth of the market. In terms of revenues, the market will expand from approximately $271 million in 2017 to over $840 million by the end of 2027, riding on healthy double-digit CAGR during the forecast period.
Based on imaging techniques, end-user, component type and applications, the market has been segmented.
With valuation worth $200 million in 2017 year, the instrument segment poised to secure a valuation of over $130 million by the end of 2027, reflecting expansion at double-digit CAGR during the assessment period.
Get Content Links from Established Websites
I Give You 23 Million Verified Emails
Buy Research Report: Serial Console Server Market to Be Valued at US$ 37 Bn by 2030 – Supply Issues amidst COVID-19 Pandemic Impeding Market Expansion
Buy Research Report: Tennis Racquet Market to Expand Nearly 1.5X through 2030 – Reduced Sports Activities Due to COVID-19 Outbreak Affecting Sales Prospects
I Give You Mega Pack WP Plugin
Buy Research Report: Indian Pan Masala Market Growth Impelled by Product Diversity
Buy Research Report: Plant Based Meat Market is a Vegan Meat Substitute to See a Strong Growth
I Give You Masterclass Poker Course by Daniel Negreanu
I Give You Masterclass Poker Course By Phil Ivey
I Give You Masterclass Poker Course by Nick Petrangelo
The software segment is projected to be valued over $40 million in 2017, is estimated to secure a valuation over $130 million by 2027-end, riding on an impressive CAGR throughout the forecast period.
An estimated valuation over $175 million secured by IHC Assay segment in 2017, is slated to hold a value of more than $555 million by the end of assessment period, while reflecting value CAGR of 12%.
The FISH assay segment is projected to witness valuation nearly $180 million by 2027-end, raised from valuation nearly $60 million in 2017, exhibiting expansion at significant CAGR throughout the forecast period.
The research segment is projected to secure value of nearly $240 million in 2017, will reflect 12% CAGR during the assessment period to reach valuation over $740 million by 2027-end.
The translational laboratories segment is projected to hold a value worth $4 million in 2017, is poised to reach a value of nearly $420 million at the end of 2027, reflecting an impressive value CAGR over the forecast period.
The study projects analysis of the market based on key region that include Latin America, Western Europe, Asia Pacific excluding Japan, North America, Eastern Europe, Middle East and Africa, and Japan. According to the report, multiplex biomarker imaging market in North America is estimated to reach a value of more than $500 million by the end of 2027, exhibiting expansion at impressive CAGR throughout the forecast period. Whereas the market in Western Europe is poised to hold valuation of nearly $210 million by the end of assessment period, reflecting a double-digit value CAGR through 2027.
The report has also profiled some leading market players that are operating in the market and are responsible for expansion of the market such as ToposNomos Ltd, Perkin Elmer, Inc., Leica Biosystems Nussloch GmbH, Thermo Fisher Scientific, Inc., Aushon BioSystems Ltd., MicroConstants, Inc., Abcam plc., Illumina Inc., Merck KGaA, Ventana Medical Systems, Inc., and Bio-rad Laboratories Inc. Some prominent players are concentrating on merging and acquisition to increase sales. Other players are focusing on targeting technologically improved emerging countries such as Asia Pacific region with availability of skilled labour and sufficient capital base.